Remove DEA Remove Legalization Remove Pharmaceutical Remove Treatment
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. The company initiated the first legal transfer (as deemed by federal law) to the U.S. territories.

article thumbnail

DEA-Licensed Biopharmaceutical Research Company to Partner with CURE Pharmaceutical to Produce Federally-Compliant Cannabis-Based Medical Products

Cannabis Law Report

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

The FDA’s approval of the drug is just one step toward getting Epidiolex on the market and available to doctors to prescribe as a treatment option. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

Cannabis Law Report

–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. OXNARD, Calif.–(BUSINESS

article thumbnail

ICYMI: DEA and Cannabis Research Still Lousy Bedfellows

Canna Law Blog

Ole Miss got the cannabis study and research cultivation gig from the DEA (via a contract with the National Institute on Drug Abuse (NIDA)) in 1968. In 2016, the DEA finally shifted to different treatment around expanded research efforts into cannabis beyond Ole Miss. These cannabis products are used by researchers in the U.S.

DEA 70
article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. A Push by Patients.

Therapy 55
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

Though it doesn’t get users high like THC-dominant products, CBD is all the rage these days due to its medical benefits and gray-area legality. On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances.

DEA 51